Guggenheim Slaps Buy Rating on CRBP: $45 Target Signals Massive Upside

Corbus Pharmaceuticals gets Buy rating ($45 target). Drug CRB-701 shows strong cancer results, safer than rivals. Stock down 43% may be opportunity.